Advent Pharmaceuticals was founded in 2001 by former GlaxoSmithKline employees, with extensive experience in respiratory R&D and commercialization.

Adventís core expertise centers on the design and development of Dry Powder Inhaler devices, formulation of medicines for optimal performance in our inhalers and global regulatory strategy.

Advents key accomplishments include:

 Adventís vipĖ novel, cartridge-based dry powder inhaler

 Advents Universal Dry Powder Inhaler Platform Ė next-generation DPI devices

These accomplishments are the result of Adventís strong, in-house technical knowledge and broad-based expertise, generating key intellectual property and know-how.

Advents Research & Development and Pilot Manufacturing facilities are based in Melbourne, Australia and are backed by a supportive investor base and founders, including CM Capital and QIC BioVentures.

 

Mr Ken Windle

CEO and Managing Director

23 Normanby Road

Notting Hill

Victoria, Australia 3168

Phone: +61 3 9544 8785

E-mail: kwindle@advent-pharma.com

Please direct all enquiries to: